uniQure(US:QURE) Globenewswire·2026-02-15 13:26Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 13, 2026 [4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA approval of the design of the Pivotal Study and downplayed the likelihood of delays in the BLA timeline [6]. - It is claimed that the results from the Pivotal Study were not fully approved by the FDA, and the company would need to conduct additional studies to support its BLA submission [6]. - The disclosure on November 3, 2025, revealed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would be adequate for BLA submission, contradicting previous statements about the path toward accelerated approval [7]. Group 2: Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [10].